A Phase 3 Randomized Study of Selumetinib (IND# 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Pediatrics Research -
Location
-
Principal Investigator
-
Sponsor
Children's Oncology Group
The overall goals of this study are to see if selumetinib works just as well as the standard treatment of carboplatin/vincristine (CV) for subjects with NF1-associated LGG, and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway.